The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is a huge mover today! About 530,503 shares traded hands. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has risen 31.35% since April 13, 2016 and is uptrending. It has outperformed by 27.42% the S&P500.
The move comes after 7 months negative chart setup for the $1.74 billion company. It was reported on Nov, 15 by Barchart.com. We have $29.58 PT which if reached, will make NASDAQ:ALDR worth $156.60M less.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Ratings Coverage
Out of 9 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alder Biopharmaceuticals has been the topic of 11 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Wells Fargo given on Thursday, April 21. The firm has “Outperform” rating by Credit Suisse given on Tuesday, March 29. The rating was maintained by Jefferies with “Buy” on Wednesday, July 27. The firm has “Buy” rating given on Wednesday, September 9 by Jefferies. JP Morgan initiated Alder Biopharmaceuticals Inc (NASDAQ:ALDR) rating on Tuesday, September 13. JP Morgan has “Overweight” rating and $40 price target. On Monday, October 31 the stock rating was initiated by Piper Jaffray with “Overweight”. As per Wednesday, April 20, the company rating was initiated by Brean Capital.
According to Zacks Investment Research, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.”
More news for Alder Biopharmaceuticals Inc (NASDAQ:ALDR) were recently published by: Fool.com, which released: “Why Alder Biopharmaceuticals Is Sky-Rocketing Today” on March 28, 2016. Nasdaq.com‘s article titled: “Oversold Conditions For Alder Biopharmaceuticals” and published on October 31, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.